IN THE COURT OF APPEAL OF NEW ZEALAND
CA8/05
BETWEENPFIZER IRELAND PHARMACEUTICALS
First AppellantANDPFIZER NEW ZEALAND LIMITED
Second Appellant
ANDELI LILLY AND COMPANY
First RespondentANDELI LILLY AND COMPANY (NEW ZEALAND) LIMITED
Second Respondent
Hearing:5 August 2005
Court:Anderson P, William Young, Chambers, O'Regan and Robertson JJ
Counsel:D Shavin QC and A H Brown QC for Appellants
R J Katz QC, J L Land and S Wheeldon for Respondents
Judgment:8 December 2005
JUDGMENT OF THE COURT
AThe appeal against the High Court judgment delivered on 3 December 2004 and the application for leave to appeal against the High Court judgment delivered on 21 November 2003 are dismissed.
BThe cross-appeal against the High Court judgment delivered on 3 December 2004 is dismissed.
CThe appellants are to pay the respondents costs of $10,000 together with usual disbursements.
DThere is a certificate for one extra counsel.
REASONS
(Given by William Young J)
Table of Contents
Para No
Introduction [1]
THE TRADITIONAL APPROACH TO THE PLEADINGS REQUIRED OF A [5]
patentee in revocation proceedings
The Ancare case [14]THE RELEVANT INTERLOCUTORY JUDGMENTS OF POTTER J
The 2003 judgment [19]
The 2004 judgment[22]
The issues in this Court [27]
Does Ancare state the law correctly? [29]
Should we grant leave to appeal against the 2003 [35]
judgment?
Should we allow the appeal against the 2004 judgment? [40]
Should we allow the cross-appeal? [44]
Result [47]Introduction
[1] We are required to deal with pleading points which arise in patent litigation between the appellants (“Pfizer”) and the respondents (“Eli Lilly”). Pfizer alleges that Eli Lilly has contravened patents associated with Viagra. Eli Lilly denies infringement but, by way of counterclaim, asserts that the Pfizer patents are invalid on the grounds set out in accompanying (and subsequently amended) particulars of objection to validity. In issue is the extent to which Pfizer must respond to the now amended particulars of objection.
[2] In judgments delivered on 21 November 2003 and 3 December 2004, Potter J required Pfizer to plead in detail to what are now amended particulars of objection. In her 21 November 2003 judgment, Potter J applied the decision of this Court in Ancare New Zealand Limited v Ciba Geigy New Zealand Ltd (1997) 11 PRNZ 398.
[3] An appeal by Pfizer, confined to the 3 December 2004 judgment and a cross‑appeal by Eli Lilly against the same judgment were listed before a bench of three Judges on 22 June 2005. It soon became apparent that the appeal was, in substantial part, a challenge to the prior decision of this Court in Ancare. Consequently the hearing was adjourned and argued before a full Court. In the meantime, Pfizer applied for leave to appeal out of time against the 21 November 2003 judgment. We heard the appeal and cross-appeal in relation to the 3 December 2004 judgment and the application for leave to appeal at the same time and all are addressed in this judgment.
[4] We note that Pfizer and Eli Lilly are involved (or…
Keep reading for free
Create a free CaseChat account to read Pfizer Ireland Pharmaceuticals v Eli Lilly and Company and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2005] NZCA 311
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi